United States was Immunocore Holdings’s largest region in fiscal 2025, bringing in $257.00M of $400.02M (64%).
| Geography | FY 2024 | FY 2025 |
|---|---|---|
| United States | $226.69M | $257.00M |
| Europe | $73.22M | $131.42M |
| International | $10.08M | $11.60M |
| Total | $309.99M | $400.02M |
Immunocore Holdings brought in $400.02M from its three regions in fiscal 2025, the year ended December 31, 2025. That was up 29.0% from $309.99M in fiscal 2024. United States was the largest at $257.00M (64.2%), ahead of Europe at $131.42M (32.9%) and International at $11.60M (2.9%).
Compared with fiscal 2024, Europe grew fastest, up 79.5% to $131.42M. Every region above 2% of revenue grew.
United States was Immunocore Holdings’s largest region in fiscal 2020, bringing in $23.76M of $30.11M (79%).
| Geography | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|
| United States | $17.58M | $19.92M | $23.76M |
| Uk | — | $5.75M | $6.36M |
| United Kingdom | $6.08M | — | — |
| Total | $23.65M | $25.67M | $30.11M |
Immunocore Holdings brought in $30.11M from its two regions in fiscal 2020, the year ended December 31, 2020. That was up 17.3% from $25.67M in fiscal 2019. United States was the largest at $23.76M (78.9%), ahead of Uk at $6.36M (21.1%).
Compared with fiscal 2019, United States grew 19.3% to $23.76M and Uk grew 10.5% to $6.36M.
Immunocore Holdings began breaking out Uk in fiscal 2019, when it brought in $5.75M. Immunocore Holdings stopped reporting United Kingdom as a separate region after fiscal 2018, when it brought in $6.08M.
Genentech was Immunocore Holdings’s largest revenue line in fiscal 2020, bringing in $20.24M of $30.11M (67%).
| Products and services [axis] | FY 2018 | FY 2019 | FY 2020 |
|---|---|---|---|
| Genentech | $1.46M | $19.10M | $20.24M |
| Med Immune | $7.55M | — | — |
| Glaxo Smith Kline | $6.08M | $5.75M | $6.36M |
| Eli Lilly | $8.56M | $819.00K | $3.52M |
| Total | $23.65M | $25.67M | $30.11M |
Immunocore Holdings brought in $30.11M from its three revenue lines in fiscal 2020, the year ended December 31, 2020. That was up 17.3% from $25.67M in fiscal 2019. Genentech was the largest at $20.24M (67.2%), ahead of Glaxo Smith Kline at $6.36M (21.1%) and Eli Lilly at $3.52M (11.7%).
Compared with fiscal 2019, Eli Lilly grew fastest, up 330.0% to $3.52M. Every revenue line above 2% of revenue grew.
Immunocore Holdings stopped reporting Med Immune as a separate revenue line after fiscal 2018, when it brought in $7.55M.
Immunocore Holdings (IMCR) reports its revenue by geography and by products and services [axis]. In fiscal 2025, United States was its largest region, bringing in $257.00M (64.2% of the total), followed by Europe at $131.42M (32.9%).
United States was Immunocore Holdings' largest region in fiscal 2025, bringing in $257.00M, or 64.2% of the $400.02M total across its three regions.
Genentech was Immunocore Holdings' largest revenue line in fiscal 2020, bringing in $20.24M, or 67.2% of the $30.11M total across its three revenue lines.
Among Immunocore Holdings' regions that make up at least 2% of revenue, Europe grew fastest in fiscal 2025, up 79.5% from $73.22M to $131.42M.
Every figure comes from Immunocore Holdings' annual financial filings, as reported. Each line keeps the name Immunocore Holdings gives it, and years follow its fiscal calendar.
Immunocore Holdings' revenue by geography goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.